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Abstract
Introduction: This study aimed to examine the recovery of spiked human cardiac troponin I (cTnI) results measured by four routine assays, and in-
vestigate possible interference from microclots.
Materials and methods: 457 consecutive samples with cTnI concentration below limit of quantitation (12 ng/L), declared by the Vitros TnI ES 
assay (reference assay), were measured on Beckman Coulter Accu TnI+3, Siemens TnI-Ultra and Roche TnI STAT assays. These samples were enriched 
with native full-length cTnI to a concentration of 100 ng/L and retested. A post-spiking result that exceeded the critical difference at a predefined 
probability of 0.0005 of the target concentration (the median post-spiking result for each individual assay) was considered as outlier. To determine 
whether microclots were a significant cause of critically discrepant outlier results, a separate 50 samples were centrifuged twice between two post-
spiking measurements using the Vitros TnI ES assay. 
Results: The median recovery of the enriched cTnI was highest with the Roche assay (271 ng/L) and lowest with the Vitros assay (29 ng/L). The 
Vitros assay had the highest percentage of results that exceeded the critical difference (49%), followed by the Siemens (38%), Roche (18%) and 
Beckman Coulter (7%) assays. None of the 50 additional samples produced a critically lower cTnI result after re-centrifugation.
Conclusions: Our findings underscored the variability of cTnI assays in measuring native cTnI. The lack of cTnI results that became significantly lower 
after re-centrifugation suggested that microclots are unlikely to be a major cause of the outlier results. 
Key words: cardiovascular diseases; troponin; immunoassay; clinical chemistry
Received: January 27, 2016 Accepted: April 25, 2016
Recovery of spiked troponin I in four routine assays
Tze Ping Loh*, Xiong Chang Lim, Karize Kieu, Haressh Sajiir, Siew Fong Neo, Wan Ling Cheng, Sunil Kumar Sethi




The diagnosis of acute myocardial infarction (AMI) 
requires the biochemical evidence of a change 
(rise or fall) in serial plasma concentration of cardi-
ac troponin (cTn) I or T, with at least one concentra-
tion above the 99th percentile upper reference 
limit (1). It also requires at least one additional sup-
porting feature involving clinical assessment, elec-
trophysiology, imaging, angiography or autopsy. 
Because of the high diagnostic weight given to 
cTn, a spurious result can have significant clinical 
consequences (2,3). Moreover, the difference in 
limit of quantification, limit of detection and upper 
reference limit among routine cTn assays may re-
sult in differing diagnostic performance and con-
fuse physicians. 
The increasingly sensitive cTn assays can amplify 
minor variations / errors in pre-analytical and ana-
lytical processes, increasing the likelihood of spuri-
ous results. Although what constitutes a signifi-
cant change between serial cTn results is still de-
bated (4), an accurate and precise assay is clearly 
necessary. Yet, the measurement of cTn is con-
founded by many factors related to patient sam-
ple such as heterophile antibodies (5,6), rheuma-
toid factors (7), troponin autoantibodies (8,9), and 
microclots or micro-particles (10). Despite im-
proved assay design, laboratory interference caus-
ing inconsistent cTn measurement remains a con-
cern (11,12). 
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The presence of interfering factors in patient sam-
ples can cause spuriously high or low cTn measure-
ments (5-12). We hypothesized that spiking of na-
tive cTn protein into patient samples and measuring 
their recovery using routine cTn assay may provide 
information about their potential susceptibility to 
these patient-specific factors. Here, we aimed to ex-
amine the recovery of spiked native human cTnI in 
patient samples using four routine cTnI assays. 
Materials and methods
Materials
The study was performed at the National Universi-
ty Hospital, Singapore, between November 2014 
and January 2015. It was performed as part of a 
pre-implementation laboratory evaluation of the 
performance of four cTnI assays and was exempt-
ed from local ethics review. The principles of the 
Declaration of Helsinki were observed throughout 
the study. 
A total of 457 consecutive leftover patient sam-
ples, collected in lithium heparinized plasma sepa-
ration tubes (catalog no. 367962, BD Vacutainer, 
BD Biosciences, Manchester, United Kingdom), 
with cTnI concentrations below the lower limit of 
quantification of the Vitros TnI ES assay (< 12 ng/L), 
were included in this study. There was no specific 
restriction on the patient population. These sam-
ples were stored at 4 °C and retrieved within 
twelve hours of the initial testing for re-analysis. 
They were not subjected to re-centrifugation prior 
to analysis. One mL of each anonymized plasma 
sample was used to measure cTnI on the other 
three assays. These results served as the baseline 
(pre-spiking) concentrations. None of these sam-
ples had elevated hemolysis, icteric or lipemic in-
dices, as determined by the Vitros 5600 platform 
using spectrophotometry principle, which may in-
terfere with the cTnI measurements. 
Subsequently, the remaining aliquots were en-
riched with native full-length (non-complexed) 
cTnI protein purified from human cardiac tissue 
(catalog no. ab9936, Abcam, Massachusetts, USA), 
which has been pre-diluted with 1X-phosphate 
buffered saline, to a final concentration of 100 
ng/L. The purity of this preparation is > 95% by vis-
ual estimation of the SDS PAGE gel, according to the 
manufacturer. This commercially acquired prepara-
tion is not traceable to any international reference 
standard. After the initial round of testing, 33 μL of 
the pre-diluted native cTnI protein was spiked into 
690 μL of the remaining aliquot of sample. The en-
riched samples were allowed to incubate at room 
temperature (~23 °C) for two hours before repeat-
ing measurement of cTnI. The measurement was 
repeated within four hours of the initial assay. 
Two trained laboratory technicians, with more 
than five years of laboratory experience each, 
carefully performed all manual laboratory proce-
dures. The variability of the manual pipetting pro-
cedures was assessed by pipetting and dispensing 
33 μL and 1 mL of water into a laboratory precision 
balance (Cubis® Analytical Balance, Sartorius 
GmbH, Goettingen, Germany). The weight of these 
volumes of water was recorded. This was per-
formed in 20 replicates for each pipetting volume. 
The coefficient of variation of the recorded weight 
of these two pipetting volumes were calculated, 
and considered the coefficient of variation of pi-
petting procedure. They were used to calculate 
the critical difference (see below). 
To determine whether outlier results were caused 
by microclots, an additional 50 aliquots of leftover 
samples were enriched with cTnI and measured on 
the Vitros TnI ES assay. Following this, these sam-
ples were immediately protected with paraffin 
film, centrifuged twice consecutively (3000 x g, for 
a total of 10 minutes, at 5 °C) using the PrO-Hospi-
tal centrifuge (Centurion Scientific, West Sussex, 
United Kingdom), and retested. The additional 
centrifugation step aimed at eliminating any free-
floating microclots that may interfere with the cTnI 
measurement. A fall in cTnI measurement after re-
centrifugation that exceeds the critical difference 
(as defined below) indicates that microclots have 
likely caused a spuriously elevated pre-centrifuga-
tion result.
Methods
The four assays under evaluation included: a) the 
Accu TnI+3 (adopted on the Beckman DxI plat-
http://dx.doi.org/10.11613/BM.2016.025 Biochemia Medica 2016;26(2):233–9 
  235
Loh TP. et al. Recovery of troponin I in four immunoassays
form, both Beckman Coulter Diagnostics, Califor-
nia, USA); b) Vitros TnI ES (adopted on the Vitros 
5600 platform, both Ortho Clinical Diagnostics, 
New York, USA); c) TnI-Ultra (adopted on the Im-
mulite 2000 XPi platform, both Siemens Medical 
Solutions Diagnostics, Munich, Germany) and d) 
TnI STAT (adopted on the Cobas e411, both Roche 
Diagnostics, Mannheim, Germany). The technical 
specifications of these assays, as reported in the 
product inserts by the manufacturers, are summa-
rized in Table 1. 
In our laboratory, cTnI is routinely measured by the 
Vitros TnI ES assay within an hour after sample col-
lection. The Vitros TnI ES assay was considered as 
reference assay in this study. 
Statistical analysis
The baseline cTnI results of all four assays were 
summarized using simple descriptive statistics. 
The mean concentration of the post-spiking sam-
ples of each assay was considered the target con-
centration. The recovery of each sample was cal-
culated as [ (measured post-spiking cTnI concen-
tration) / (100 ng/L, the spiked cTnI concentration) 
× 100% ]. The percentage difference between the 
post-spiking cTnI concentration in each individual 
sample and the target concentration was calculat-
ed as [ (measured cTnI concentration after spiking 
a particular sample) - (assay-specific target cTnI 
concentration) / (assay-specific target cTnI concen-
tration) × 100%]. A percentage difference between 
the post-spiking results and the target concentra-
tion of more than [z-score x 2 0.5 x (analytical coef-
ficient of variation near the target concentration2 
+ coefficient of variation of pipetting procedure2) 
0.5] was considered critically different. A z-score of 
3.5, corresponding to a predefined probability of 
0.0005, was selected in this study. A result is consid-
ered an outlier if the recovery exceeds the critical 
difference of the target concentration. Two-tailed 
Fisher’s exact test was performed to determine 
whether the difference in the proportion of outlier 
results between any two of the four routine assays 
were statistically significant (defined as P < 0.05). 
Results
The number of pre-spiking samples and their con-
centrations above the lower limit of quantification 
of the other three assays are summarized in Table 
2. Two of the seven results that were above the up-
per reference limit belonged to the same sample 
and were high on Siemens cTnI-Ultra and Beck-
man Coulter Accu TnI+3 assays, respectively. 
The post-spiking cTnI concentrations measured by 
the four assays are summarized in Figure 1. The 
within-assay and between-assays recoveries of the 
enriched cTnI were highly variable. The Siemens 
TnI-Ultra assay had the widest range of enriched 
cTnI concentration recovered. 
The coefficient of variation of the manual pipet-






















Vitros TnI ES 12 12 40 27 4.3% at 70 ng/L 23.1
Beckman Coulter Accu 
TnI+3 8 40 40 40 8.0% at 50 ng/L 40.6
Siemens cTnI-Ultra 6 30 40 30 5.3% at 80 ng/L 27.7
Roche TnI STAT 160 300 160 234 4.8% at 323 ng/L 25.4
CV - coefficient of variation. 
The critical difference was calculated as [4.95 × (analytical coefficient of variation near the target concentration2 + coefficient of 
variation of pipetting procedure2) 0.5], at a predefined probability of 0.0005. 
Table 1. Technical specifications reported by the manufacturers’ product inserts of the assays used 
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of the four assays are provided in Table 1. The 
number of samples that exceeded the critical dif-
ference is summarized in Table 3. Using two-tailed 
Fisher exact test, all combinations of pair-wise be-
tween-assay comparison of the proportion of 
samples with recovery exceeding the critical dif-
ference were significantly different (P < 0.05); ex-
cept for samples with positive difference exceed-
ing the critical difference measured by the Vitros 
TnI ES and the Siemens cTnI-Ultra assays.
The Vitros TnI ES assay had the highest percentage 
(49%) of results that are outliers, followed by the 
Siemens TnI-Ultra (38%), Roche TnI STAT (18%) and 
Beckman Coulter Accu TnI+3 (7%) assays. Fifty-five 
samples had post-spiking results that were above 
the target concentration in some assays, and be-
low the target concentration in others (i.e. discord-
ant recoveries between assays).
Of the 50 samples that were re-centrifuged twice 
between cTnI measurements, none produced a 
critically lower post-re-centrifugation cTnI result. 
Only one sample had critically discrepant cTnI re-
sult that was higher after re-centrifugation (pre-re-
centrifugation: 22 ng/L vs. post-re-centrifugation: 
Assay













Beckman Coulter AccuTnI+3 2 60 25 42–77 2 42–77
Siemens cTnI-Ultra 13 39 11 33–68 2 51–68
Roche TnI STAT 3 410 80 330–480 3 330–480
Table 2. Pre-spiking samples above the limit of quantification of the three assays investigated and their concentrations. 







Vitros TnI ES 23.1 95 (21) 234 (51) 128 (28)
Beckman Coulter AccuTnI+3 40.6 23 (5) 426 (93) 8 (2)
Siemens cTnI-Ultra 27.7 115 (25) 283 (62) 59 (13)
Roche TnI STAT 25.4 37 (8) 375 (82) 45 (10)
Table 3. Samples exceeding the critical difference (at a predefined probability of 0.0005). 
Figure 1. Box and whisker plots showing the post-spiking car-
diac troponin I result in the four assays. 
The y-axis is in logarithmic scale and the grey horizontal bar 
represents the upper reference limit of the respective assays. Val-
ues below the figure summarize the median and range of con-
centration of troponin I in the post-spiking samples, the median 
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29 ng/L, translating into a 27% difference). The rest 
of the results are summarized in Table 4. 
Discussion
The baseline cTnI results were highly comparable 
across the four assays. There were only seven dis-
cordant results where the cTnI was elevated above 
the upper reference limit when measured by an-
other assay. Interestingly, only one sample had dis-
cordant results in more than one laboratory meth-
od. This particularly sample had elevated cTnI 
measured by the Siemens cTnI-Ultra and Beckman 
Coulter Accu TnI+3 assays, and was negative on 
the others. This suggests that there may be pa-
tient-specific factors that infrequently affect the 
individual assays, causing discordant cTnI results.
As the cTnI concentration of these pre-spiking pa-
tient samples were consistently suppressed across 
multiple assays, we could assume that they were 
truly negative for cTnI. Hence, the clinical specifici-
ty [true negative / (true negative + false positive) x 
100%] of these assays is > 99%. This is generally in 
accordance with other clinical studies, which 
showed very high clinical specificity (> 90%) for 
cTnI assays in situations where the difference be-
tween serial measurements is small (4). 
Many studies have looked at the prevalence of an-
alytical interference in cTnI assays. Some of these 
studies have relied on finding discrepant results 
from duplicate testing of the same sample (12), 
while others directly evaluated the effect of a spe-
cific interfering factor on cTnI measurement (9,11), 
which includes heterophile antibodies (5,6), rheu-
matoid factors (7), troponin autoantibodies (8,9), 
and microclots or micro-particles (10).
The use of recovery experiment is one of the rou-
tine methods for screening for laboratory interfer-
ence (13,14). When the measured concentration 
(i.e. recovery) of a target analyte is significantly 
higher or lower than the spiked concentration, it 
indicates that the sample may contain substances 
that interfered with the laboratory measurement 
procedure. The spiking experiment design used in 
this study seeks to simulate an AMI event, where a 
patient with no measurable baseline cTnI is sud-
denly exposed (via ex vivo enrichment) to low con-
centrations of cTnI. The concentration of cTnI used 
in this study was deliberately kept low to enhance 
the sensitivity of the detection of potential assay 
interference. This study provides complementary 
data to the other experimental designs by looking 
at the how the different routine cTnI assays react 
with spiked native human cTnI protein in a large 
cohort of patient with no detectable cTnI at base-
line. The native full-length (non-complexed) cTnI 
protein purified from human cardiac tissue is used 
as a standardized spiking material for this recovery 
experiment since the cTnI assays are designed to 
measure this molecule. Therefore, it provides a ho-
mogenous target molecule against which the per-
formance of the assays can be assessed. 
Under this experimental design, the prevalence of 
outlier cTnI results is highly variable among the 
four assays. The high number of outlier result seen 
in the Vitros TnI ES assay can be explained by the 
low cTnI recovery (low denominator), coupled with 
the high assay precision resulting in a small critical 
difference. 
Several factors may contribute to highly variable 
recoveries of cTnI between the assays. Human cTnI 
is a heterogeneous group of molecules. They in-
Troponin I, ng/L Pre-re-centrifugation Post-re-centrifugation % Difference
Mean 35 36 - 3
Median 32 33 - 3
Minimum 12 13 - 28
Maximum 76 77 13
Percent difference (%) was calculated as [ (pre-re-centrifugation result - post-centrifugation result / pre-re-centrifugation result) × 100]. 
Table 4. Pre- and post-re-centrifugation cardiac troponin I results. 
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clude different isoforms (15,16) and complexes 
(17,18), and are degraded into various lengths by 
proteases in blood (19,20). Significant systematic 
inter-method differences among cTnI assays are 
probably influenced by differences in standardisa-
tion, the use proprietary antibodies that have dif-
ferent cross-reactivities to different forms of cTnI, 
and different upper reference limits (17-20). Hence, 
the antibodies of the assay are likely to have differ-
ent degree of recognition of the native human cTnI 
spiked into the sample, leading to the observed 
differences in the amount recovered. 
On the other hand, the heterogeneity in cTnI re-
covery among patient samples when using the 
same assay probably reflects patient-specific inter-
fering factors. This is particularly true since the 
same amount of native human cTnI was enriched 
in each sample. Recently, cTn autoantibodies have 
been gaining increasing attention as a common 
laboratory interferent. cTn auto-antibodies can af-
fect the assay by inhibiting the interaction of the 
assay antibody and the cTn epitope (9,11). On the 
other hand, it may also form ‘macro-cTn’ and cause 
spuriously elevated measurement as a result of im-
paired clearance (21), which may be associated 
with chronically elevated cTnI (22). The prevalence 
of cTn autoantibodies has been reported to be 
present in 12.7% to 15.9% of the general popula-
tion (23,24). It is conceivable that some of the sam-
ples with recoveries that exceeded the critical dif-
ference were due to the presence of cTnI autoanti-
bodies. 
There have been reports of irreproducible, falsely 
high cTnI results that are commonly referred to as 
“outliers” (or colloquially known as “fliers”). Typi-
cally, these results are detected upon repeat test-
ing of the same sample that would return a differ-
ence that is significantly larger than the analytical 
variation of the instrument (12,25,26). The preva-
lence of these outlier results have been reported 
to be < 1% in several recent studies (25-27). They 
are more common in samples that have been 
stored (26) and are unrelated to the analyser, cen-
trifugation speed or sample type (27). The cause of 
such phenomenon is yet unclear, but fibrin strands 
have been suggested as a possibility (25). 
Microlots / fibrin strands can cause spuriously ele-
vated cTnI results. In this study, the double re-cen-
trifugation of the 50 clinical samples did not pro-
duce any significantly lower result. This suggested 
that microclots / microparticles were unlikely to be 
a major interfering factor in this study.
Of note, the number of samples with post-spiking 
cTnI results above the upper reference limit was 
also highly variable. Clinically, this may indicate 
that different troponin assays have different ability 
to discriminate patients with raised cTnI, leading to 
variable clinical diagnostic performance.
There are several potential limitations in this study. 
The observed differences in measured concentra-
tions between the assays may be in part related to 
between-method bias, which was not examined 
in this study, and should be interpreted with care. 
Additionally, the identity of the interfering factor 
in the critically discrepant samples was not exam-
ined in detail, as it was beyond the scope of this 
study. A detailed study of the prevalence of inter-
fering factors affecting routine cTnI assays is an im-
portant area for further research. Finally, there was 
no specific restriction on the patient population 
included in this study. It is conceivable that some 
of these patients may have treatment such as hep-
arin that may affect cTn measurement (28). 
In conclusion, our findings underscored the varia-
bility of cTnI assays in measuring native cTnI. The 
lack of cTnI results that became significantly lower 
after re-centrifugation suggested that microclots 
are unlikely to be a major cause of the outlier re-
sults.
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